BlackRock’s Capricor Therapeutics CAPR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $104M | Buy |
3,421,815
+570,837
| +20% | +$15.2M | ﹤0.01% | 2084 |
|
|
2025
Q4 | $82.3M | Sell |
2,850,978
-19,194
| -0.7% | -$251K | ﹤0.01% | 2230 |
|
|
2025
Q3 | $20.7M | Sell |
2,870,172
-113,891
| -4% | -$839K | ﹤0.01% | 3072 |
|
|
2025
Q2 | $29.6M | Buy |
2,984,063
+39,398
| +1% | +$416K | ﹤0.01% | 2795 |
|
|
2025
Q1 | $27.9M | Sell |
2,944,665
-22,249
| -0.7% | -$309K | ﹤0.01% | 2740 |
|
|
2024
Q4 | $40.9M | Buy |
2,966,914
+1,216,907
| +70% | +$21.3M | ﹤0.01% | 2580 |
|
|
2024
Q3 | $26.6M | Buy |
1,750,007
+121,457
| +7% | +$601K | ﹤0.01% | 2853 |
|
|
2024
Q2 | $7.77M | Buy |
1,628,550
+1,246,815
| +327% | +$6.95M | ﹤0.01% | 3512 |
|
|
2024
Q1 | $2.59M | Buy |
381,735
+22,062
| +6% | +$107K | ﹤0.01% | 3907 |
|
|
2023
Q4 | $1.76M | Buy |
359,673
+1,099
| +0.3% | +$3.58K | ﹤0.01% | 4087 |
|
|
2023
Q3 | $1.23M | Sell |
358,574
-52,347
| -13% | -$294K | ﹤0.01% | 4187 |
|
|
2023
Q2 | $1.96M | Buy |
410,921
+16,941
| +4% | +$74.4K | ﹤0.01% | 4062 |
|
|
2023
Q1 | $1.66M | Sell |
393,980
-44,930
| -10% | -$193K | ﹤0.01% | 4130 |
|
|
2022
Q4 | $1.69M | Buy |
438,910
+1,682
| +0.4% | +$8.03K | ﹤0.01% | 4201 |
|
|
2022
Q3 | $2.62M | Buy |
437,228
+138,347
| +46% | +$708K | ﹤0.01% | 4051 |
|
|
2022
Q2 | $1.04M | Sell |
298,881
-3,638
| -1% | -$12.9K | ﹤0.01% | 4517 |
|
|
2022
Q1 | $1.04M | Sell |
302,519
-465
| -0.2% | -$1.83K | ﹤0.01% | 4654 |
|
|
2021
Q4 | $888K | Buy |
302,984
+2,783
| +0.9% | +$9.75K | ﹤0.01% | 4704 |
|
|
2021
Q3 | $1.21M | Sell |
300,201
-4,842
| -2% | -$22K | ﹤0.01% | 4507 |
|
|
2021
Q2 | $1.56M | Sell |
305,043
-42,060
| -12% | -$178K | ﹤0.01% | 4373 |
|
|
2021
Q1 | $1.62M | Buy |
347,103
+4,092
| +1% | +$23.6K | ﹤0.01% | 4357 |
|
|
2020
Q4 | $1.18M | Buy |
343,011
+1,488
| +0.4% | +$6.45K | ﹤0.01% | 4176 |
|
|
2020
Q3 | $1.79M | Buy |
341,523
+307,397
| +901% | +$1.79M | ﹤0.01% | 3933 |
|
|
2020
Q2 | $157K | Buy |
34,126
+33,523
| +5,559% | +$146K | ﹤0.01% | 4411 |
|
|
2020
Q1 | $1K | Hold |
603
| – | – | ﹤0.01% | 4882 |
|
|
2019
Q4 | $1K | Hold |
603
| – | – | ﹤0.01% | 4905 |
|
|
2019
Q3 | $2K | Buy |
603
+1
| +0.2% | +$3 | ﹤0.01% | 4862 |
|
|
2019
Q2 | $2K | Sell |
602
-3,703
| -86% | -$15.5K | ﹤0.01% | 4903 |
|
|
2019
Q1 | $20K | Sell |
4,305
-210
| -5% | -$1.08K | ﹤0.01% | 4598 |
|
|
2018
Q4 | $18K | Sell |
4,515
-15
| -0.3% | -$119 | ﹤0.01% | 4598 |
|
|
2018
Q3 | $48K | Buy |
4,530
+180
| +4% | +$2.14K | ﹤0.01% | 4544 |
|
|
2018
Q2 | $59K | Buy |
4,350
+3,938
| +956% | +$53.6K | ﹤0.01% | 4538 |
|
|
2018
Q1 | $6K | Sell |
412
-150
| -27% | -$2.6K | ﹤0.01% | 4697 |
|
|
2017
Q4 | $9K | Buy |
562
+24
| +4% | +$519 | ﹤0.01% | 4645 |
|
|
2017
Q3 | $16K | Buy |
538
+40
| +8% | +$479 | ﹤0.01% | 4628 |
|
|
2017
Q2 | $4K | Sell |
498
-1,422
| -74% | -$26K | ﹤0.01% | 4812 |
|
|
2017
Q1 | $65K | Buy |
+1,920
| New | +$53.3K | ﹤0.01% | 4418 |
|
Other funds holding CAPR
SCM
TCM
VCM
RCM
JHC
BlackRock's CAPR Position: Q1 2026 in Review
BlackRock increased its Capricor Therapeutics (CAPR) stake by 20% in Q1 2026, buying an estimated $15.2M and bringing the position to 3,421,815 shares worth $104M. The position accounts for ﹤0.01% of the portfolio, ranked #2084.
BlackRock first reported a position in CAPR in Q1 2017 and has held it in 37 quarters since. 177 funds tracked by Wall St. Rank hold CAPR as of Q1 2026.
- BlackRock held 3,421,815 shares of Capricor Therapeutics worth $104M as of Q1 2026.
- BlackRock bought 570,837 Capricor Therapeutics shares in Q1 2026, an estimated $15.2M.
- Capricor Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #2084 holding.
- BlackRock first reported a position in Capricor Therapeutics in Q1 2017 and has held it in 37 quarters since.
- 177 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q1 2026.
Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.